Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes

Producción científica: Review articlerevisión exhaustiva

202 Citas (Scopus)

Resumen

Both as monotherapy and in combination with other OHAs, timed bromocriptine (Cycloset) causes a 0.6-0.7%reduction in HbA1c and reduces plasma triglyceride and FFA concentrations in type 2 diabetic patients. In a 52-week safety study, Cycloset decreased the cardiovascular composite end point by 40%. Other advantages of Cycloset include absence of hypoglycemia since insulin secretion is not stimulated, weight neutrality, no need for dose adjustment in patients with moderate renal insufficiency, lack of edema and CHF, and good side effect profile.

Idioma originalEnglish (US)
Páginas (desde-hasta)789-794
Número de páginas6
PublicaciónDiabetes care
Volumen34
N.º4
DOI
EstadoPublished - abr 2011

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Huella

Profundice en los temas de investigación de 'Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes'. En conjunto forman una huella única.

Citar esto